News|Videos|September 29, 2026

Oncology Pulsepoint: How ASCO’s New Breast Cancer Surveillance Guideline Changes Follow-Up

Fact checked by: Kirsty Mackay

In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, manager of oncology clinical pharmacy services at Allegheny Health Network in Pittsburgh, discusses ASCO’s updated guideline for follow-up and surveillance after primary treatment for early-stage breast cancer.

In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, manager of clinical pharmacy services at Allegheny Health Network in Pittsburgh, discusses ASCO’s updated guideline for follow-up and surveillance after primary treatment for early-stage breast cancer. The update introduces a risk-based approach that groups patients by the intensity of surveillance they require, moving away from a single follow-up schedule for all patients.

Related to this article